When the meta-analysis was restricted to studies conducted in the ICU setting (9 studies) the risk for secondary infections was higher for patients treated with Il-6 (receptor) antagonists compared to patients not treated with IL-6 (receptor) antagonists: RR 1.26 (95% CI 1.08 to 1.82) I2 of 52%. Here, IL6 is linked to infection.